Search Results - "O'CONNOR, O. A"

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma by Horwitz, S., O'Connor, O.A., Pro, B., Trümper, L., Iyer, S., Advani, R., Bartlett, N.L., Christensen, J.H., Morschhauser, F., Domingo-Domenech, E., Rossi, G., Kim, W.S., Feldman, T., Menne, T., Belada, D., Illés, Á., Tobinai, K., Tsukasaki, K., Yeh, S.-P., Shustov, A., Hüttmann, A., Savage, K.J., Yuen, S., Zinzani, P.L., Miao, H., Bunn, V., Fenton, K., Fanale, M., Puhlmann, M., Illidge, T.

“…For patients with peripheral T-cell lymphoma (PTCL), outcomes using frontline treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)…”
Get full text

Efficacy of chidamide maintenance therapy versus autologous stem cell transplantation versus observation as a post-remission choice in the survival of adult patients with peripheral T-cell lymphoma: Post hoc analysis of a prospective, multicenter, phase 2 study in China by Wang, Wei, Zhang, Wei, Su, Li-ping, Liu, Li-hong, Gao, Yu-huan, Wang, Quan-shun, Su, Hang, Song, Yu-qin, Zhang, Hui-lai, Shen, Jing, Jing, Hong-mei, Wang, Shu-ye, Cen, Xi-nan, Liu, Hui, Liu, Ai-chun, Li, Zeng-jun, Luo, Jian-min, He, Jian-xia, Wang, Jing-wen, O’Connor, O. A., Zhou, Dao-bin

“…In this prospective, multicenter, Phase 2 clinical trial (NCT02987244), patients with peripheral T-cell lymphomas (PTCLs) who had responded to first-line…”
Get full text

The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study by Zhang, Wei, Su, Liping, Liu, Lihong, Gao, Yuhuan, Wang, Quanshun, Su, Hang, Song, Yuhuan, Zhang, Huilai, Shen, Jing, Jing, Hongmei, Wang, Shuye, Cen, Xinan, Liu, Hui, Liu, Aichun, Li, Zengjun, Luo, Jianmin, He, Jianxia, Wang, Jingwen, O'Connor, O A, Zhou, Daobin

“…To assess the efficacy and safety of the novel histone deacetylase inhibitor, chidamide, in combination with cyclophosphamide, doxorubicin, vincristine,…”
Get full text

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study by Goy, A., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J., de Vos, S., Epner, E., Krishnan, A., Leonard, J. P., Lonial, S., Nasta, S., O'Connor, O. A., Shi, H., Boral, A. L., Fisher, R. I.

“…Background: We previously reported results of the phase 2, multicenter PINNACLE study, which confirmed the substantial single-agent activity of bortezomib in…”
Get full text

Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma by O'Connor, O A

“…Preclinical studies indicate that vorinostat (suberoylanilide hydroxamic acid or SAHA) inhibits histone deacetylase (HDAC) activity, increases acetylated…”
Get full text

P1278: ACTIVATION OF THE NECROPTOSIS PATHWAY PLAYS A ROLE IN SYNERGISM WITH COMBINATION OF THE IAP ANTAGONIST, TOLINAPANT AND HYPOMETHYLATING AGENTS (HMA) IN IN VITRO MODELS OF T‐CELL LYMPHOMA (TCL) by Manavalan, J. S., Pal, I., Pursley, A., Ward, G., Smyth, T., Sims, M., Feith, D., Loughran, T. P., O'Connor, O. A., Marchi, E.

Get full text

A Population Pharmacokinetic and Pharmacodynamic Evaluation of Pralatrexate in Patients With Relapsed or Refractory Non-Hodgkin's or Hodgkin's Lymphoma by Mould, DR, Sweeney, K, Duffull, SB, Neylon, E, Hamlin, P, Horwitz, S, Sirotnak, F, Fleisher, M, Saunders, ME, O'Connor, OA

“…In a pralatrexate phase I study, patients displayed a high incidence of mucositis of grades 3 and 4. Preliminary evaluations of the pharmacokinetics of the…”
Get full text

S217: PRELIMINARY ANALYSIS OF THE PHASE II STUDY USING TOLINAPANT (ASTX660) MONOTHERAPY IN 98 PERIPHERAL T‐CELL LYMPHOMA AND 51 CUTANEOUS T‐CELL LYMPHOMA SUBJECTS WITH RELAPSED REFRACTORY DISEASE by Michot, J.‐M., Mehta, A., Samaniego, F., Bachy, E., Zinzani, P. L., Prica, A., Colins, G. P., Ribrag, V, Wagner‐Johnston, N., El‐Sharkawi, D., O'Connor, O. A., Wilcox, R., Wang, L., Wilson, L., Sims, M., Taylor, J. A., Keer, H. N., Foss, F.

Get full text

Synthesis and Preclinical Development of a Promising Novel Romidepsin Nanoparticle for the Treatment of Peripheral T‐Cell Lymphoma (PTCL) by O'Connor, O. A., Illendula, A., Jayappa, K. D., Fox, T. E., Loughran, T. P., Feith, D. J., Marchi, E., Pal, I.

Get full text

Identifying the mechanistic differences between hypomethylating agents for the treatment of peripheral T cell lymphoma by Pal, I., Scotto, L., Sabzevari, A., Kinahan, C., Fox, T. E., Feith, D. J., Marchi, E., Loughran, T. P., O'Connor, O. A.

Get full text

Pembrolizumab in combination with epigenetic therapy is safe and active in heavily treated patients with peripheral T‐cell lymphoma and cutaneous T‐cell lymphoma by Roberts, N. L., Lister, J., Benani, N. N., Jain, S., Battaglia, T., Abdelmalek, M., Ayers, E. C., Portell, C., Williams, M. E., Batchala, P., Pal, I., Manavalan, J. S., O'Connor, O. A., Marchi, E.

Get full text

TG‐1701, A SELECTIVE BRUTON TYROSINE KINASE (BTK) INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH UBLITUXIMAB AND UMBRALISIB (U2) IN PATIENTS WITH B‐CELL MALIGNANCIES by Cheah, C. Y, Jurczak, W, Lasica, M, Wickham, N, Wróbel, T, Walewski, J, Yannakou, C. K, Cheung, S, Lewis, K. L, Długosz‐Danecka, M, Giannopoulos, K, Miskin, H. P, Tang, J.‐P, Normant, E, O'Connor, O. A, Ricart, A. D, Tam, C. S

Get full text

Effects of sterilization methods on the physical characteristics of soil: implications for sorption isotherm analyses by LOTRARIO, J. B, STUART, B. J, LAM, T, ARANDS, R. R, O'CONNOR, O. A, KOSSON, D. S

“…Laboratory studies of contaminant partitioning and transport behavior are dependent upon the exclusion of biological activity from the experimental system…”
Get full text

Metabolism of toxic pyrrolizidine alkaloids from tansy ragwort (Senecio jacobaea) in ovine ruminal fluid under anaerobic conditions by CRAIG, A. M, LATHAM, C. J, BLYTHE, L. L, SCHMOTZER, W. B, O'CONNOR, O. A

“…Classifications Services AEM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Effects of Six Different Functional Groups and Their Position on the Bacterial Metabolism of Monosubstituted Phenols under Anaerobic Conditions by O'Connor, Owen A, Young, L. Y

“…The biodegradability of phenol and all isomers of aminophenol (AP), chlorophenol (CP), hydroxybenzoate (HB), dihydroxybenzene (DHB), methylphenol (MP), and…”
Get full text

An Electrodiagnostic Evaluation of the Effect of Pre-existing Peripheral Nervous System Disorders in Patients Treated with the Novel Proteasome Inhibitor Bortezomib by Stubblefield, M.D., Slovin, S., MacGregor-Cortelli, B., Muzzy, J., Scher, H., Wright, J., Esseltine, D., Schenkein, D., O'Connor, O.A.

“…Bortezomib (Velcade ®), a novel proteasome inhibitor, has shown promise in the treatment of malignancies, including multiple myeloma and non-Hodgkin's…”
Get full text

The Synthesis, Discovery, and Development of a Highly Promising Class of Microtubule Stabilization Agents: Curative Effects of Desoxyepothilones B and F against Human Tumor Xenografts in Nude Mice by Chou, Ting-Chao, O'Connor, Owen A., Tong, William P., Guan, Yongbiao, Zhang, Zui-Guo, Stachel, Shawn J., Lee, Chulbom, Danishefsky, Samuel J.

“…We have evaluated two synthetic epothilone analogues lacking the 12,13-epoxide functionality, 12,13-desoxyepothilone B (dEpoB), and 12,13-desoxyepothilone F…”
Get full text

DEVELOPING IMMUNOEPIGENETIC PLATFORMS FOR PERIPHERAL T‐CELL LYMPHOMA: LEVERAGING A LOGIC FOR PD1/PDL‐1 INHIBITORS by O'Connor, O.A.

Get full text

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023 by Pal, I, Scotto, L, Sabzevari, A, Kinahan, C, Fox, T E, Feith, D J, Marchi, E, Loughran, Jr, T P, O'Connor, O A

Get full text

Apoptosis: from biology to therapeutic targeting by O'Connor, O.A.

Get full text